Daratumumab, an anti-CD38 monoclonal antibody targeting plasma cells, has emerged as a potential therapy for recurrent focal segmental glomerulosclerosis (FSGS) after kidney transplantation; however, data on subcutaneous administration and its use in de novo d... ...

请注册登录后继续浏览